CalciMedica, Inc. financial data

Symbol
CALC on Nasdaq
Location
La Jolla, CA
Fiscal year end
31 December
Latest financial report
10-Q - Q3 2025 - 12 Nov 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 514% % 11%
Debt-to-equity 154% % 163%
Return On Equity -296% % -163%
Return On Assets -117% % -64%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 13,972,177 shares 30%
Common Stock, Shares, Outstanding 14,257,234 shares 32%
Entity Public Float $27,900,000 USD 138%
Common Stock, Value, Issued $4,000 USD 33%
Weighted Average Number of Shares Outstanding, Basic 15,076,456 shares 35%
Weighted Average Number of Shares Outstanding, Diluted 15,076,456 shares 35%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense $15,958,000 USD 19%
General and Administrative Expense $8,950,000 USD 0.31%
Operating Income (Loss) $24,908,000 USD -11%
Nonoperating Income (Expense) $1,848,000 USD -79%
Income Tax Expense (Benefit) $0 USD -100%
Net Income (Loss) Attributable to Parent $23,060,000 USD -70%
Earnings Per Share, Basic -1 USD/shares -110%
Earnings Per Share, Diluted -1 USD/shares -110%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value $5,470,000 USD -40%
Cash, Cash Equivalents, and Short-term Investments $14,100,000 USD -3.4%
Assets, Current $14,853,000 USD -5.3%
Property, Plant and Equipment, Net $49,000 USD -62%
Assets $14,913,000 USD -8%
Accounts Payable, Current $1,133,000 USD -26%
Liabilities, Current $3,681,000 USD -2.7%
Liabilities $15,181,000 USD 111%
Accumulated Other Comprehensive Income (Loss), Net of Tax $1,000 USD -75%
Retained Earnings (Accumulated Deficit) $178,566,000 USD -15%
Stockholders' Equity Attributable to Parent $268,000 USD -103%
Liabilities and Equity $14,913,000 USD -8%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities $4,878,000 USD -3.5%
Net Cash Provided by (Used in) Financing Activities $10,742,000 USD -44%
Net Cash Provided by (Used in) Investing Activities $1,243,000 USD 91%
Common Stock, Shares Authorized 500,000,000 shares 0%
Common Stock, Shares, Issued 14,257,234 shares 32%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect $4,621,000 USD 277%
Deferred Tax Assets, Valuation Allowance $88,460,000 USD 7.1%
Deferred Tax Assets, Gross $88,475,000 USD 7.1%
Depreciation $58,000 USD -3.3%
Payments to Acquire Property, Plant, and Equipment $9,000 USD
Comprehensive Income (Loss), Net of Tax, Attributable to Parent $23,063,000 USD -70%
Deferred Tax Assets, Operating Loss Carryforwards $62,407,000 USD 6.6%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 10,000,000 shares 0%
Unrecognized Tax Benefits $11,482,000 USD 3.6%
Preferred Stock, Shares Outstanding 0 shares
Deferred Tax Assets, Net of Valuation Allowance $0 USD
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%